Acinetobacter baumannii is a Gram-negative, non-lactose-fermenting organism that causes serious nosocomial infections such as ventilator-associated pneumonia and bacteremia. A. baumannii is characterized by its tendency to acquire resistance to various classes of antimicrobials that are otherwise effective against this organism. In Pittsburgh, there is a surge in imipenem-resistant and amikacin-resistant A. baumannii, necessitating use of salvage agents such as colistin and tigecycline. Despite the potential magnitude of the problem caused by these multidrug-resistant (MDR) A. baumannii strains, little is known about the mechanisms of resistance to these antimicrobials in A. baumannii in the United States. Current epidemiological studies using pulsed-field gel electrophoresis (PFGE) reveal that A. baumannii causes nosocomial outbreaks, spreading from patient to patient mostly by contact with the contaminated hands of healthcare workers or the hospital environment. A molecular typing method that is more standardized and objective than PFGE is needed for use in surveillance studies to investigate national and international epidemiology of A. baumannii. The hypotheses of the application are: (1) OXA-type carbapenemases (e.g., OXA-23) and ArmA 16S ribosomal RNA methylase are the primary mechanisms by which A. baumannii develops resistance to imipenem and amikacin, (2) The multi-locus variable number of tandem repeats analysis (MLVA) scheme of molecular typing accurately and reliably discriminates clinical strains of A. baumannii and offers advantages over PFGE. To address these hypotheses, the following specific aims have been formulated: (1) Characterize the molecular mechanisms of imipenem and amikacin resistance in MDR A. baumannii clinical strains, (2) Evaluate objective molecular typing methods of A. baumannii. Typing results for MLVA will be compared with PFGE and MLST. The proposed study will enhance the level of understanding in how A. baumannii acquires multidrug resistance and lead to a strategy to best utilize the existing classes of antimicrobials to manage the infections. This will also form the basis for efforts in designing novel therapeutic agents and strategies that will overcome or evade the existing and emerging resistance mechanisms. Objective molecular typing methods will serve as an essential tool for future studies that will address the global epidemiology of MDR A. baumannii.

Public Health Relevance

Acinetobacter baumannii is a problematic pathogen that causes serious infections in patients admitted to hospitals. The project aims to examine how it acquires resistance to two important antibiotics, imipenem and amikacin, and also develop an objective method to """"""""fingerprint"""""""" the strains. Such knowledge will help in optimizing use of existing antibiotics and improving infection control practices.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Career Transition Award (K22)
Project #
5K22AI080584-02
Application #
7933960
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Korpela, Jukka K
Project Start
2009-09-18
Project End
2013-07-31
Budget Start
2010-08-01
Budget End
2013-07-31
Support Year
2
Fiscal Year
2010
Total Cost
$107,960
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Bueno, Maria Fernanda C; Francisco, Gabriela R; O'Hara, Jessica A et al. (2013) Coproduction of 16S rRNA methyltransferase RmtD or RmtG with KPC-2 and CTX-M group extended-spectrum ?-lactamases in Klebsiella pneumoniae. Antimicrob Agents Chemother 57:2397-400
Doi, Yohei; Park, Yoon Soo; Rivera, Jesabel I et al. (2013) Community-associated extended-spectrum ?-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 56:641-8
Hazirolan, Gulsen; Canton, Emilia; Sahin, Selma et al. (2013) Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii. Antimicrob Agents Chemother 57:4841-7
Fukuta, Yuriko; Muder, Robert R; Agha, Mounzer E et al. (2013) Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infect Control 41:1249-52
O'Hara, Jessica A; Ambe, Lauretta A; Casella, Leila G et al. (2013) Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother 57:2103-8
Kadouri, Daniel E; To, Kevin; Shanks, Robert M Q et al. (2013) Predatory bacteria: a potential ally against multidrug-resistant Gram-negative pathogens. PLoS One 8:e63397
Rogers, Benjamin A; Doi, Yohei (2013) Who is leading this dance? Understanding the spread of Escherichia coli sequence type 131. Infect Control Hosp Epidemiol 34:370-2
O'Hara, Jessica A; McGann, Patrick; Snesrud, Erik C et al. (2013) Novel 16S rRNA methyltransferase RmtH produced by Klebsiella pneumoniae associated with war-related trauma. Antimicrob Agents Chemother 57:2413-6
Pelletier, Mark R; Casella, Leila G; Jones, Jace W et al. (2013) Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 57:4831-40
Qureshi, Zubair A; Paterson, David L; Potoski, Brian A et al. (2012) Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108-13

Showing the most recent 10 out of 26 publications